Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Moon CS, Reglero C, Cortes JR, S Quinn A, Alvarez S, Zhao J, et al. induces NF-κB signaling-driven peripheral T cell lymphoma. Nat Cancer. 2021;2(1):98-113.

Mostyka M, Fulmer CG, Hissong EM, Yantiss RK. Crohn Disease Infrequently Affects the Appendix and Rarely Causes Granulomatous Appendicitis. Am J Surg Pathol. 2021.

DeSimone RA, Costa VA, Kane K, Sepulveda JL, Ellsworth GB, Gulick RM, et al. Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. Transfusion. 2021;61(3):692-698.

Beg S, Bareja R, Ohara K, Eng KW, Wilkes DC, Pisapia DJ, et al. Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. Transl Oncol. 2021;14(1):100944.

Alpert T, Brito AF, Lasek-Nesselquist E, Rothman J, Valesano AL, MacKay MJ, et al. Early introductions and community transmission of SARS-CoV-2 variant B.1.1.7 in the United States. medRxiv. 2021.

Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al. Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Adv Mater. 2021:e2100096.

Skaro M, Hill M, Zhou Y, Quinn S, Davis MB, Sboner A, et al. Are we there yet? A machine learning architecture to predict organotropic metastases. BMC Med Genomics. 2021;14(1):281.

Peters TL, Patil T, Le AT, Davies KD, Brzeskiewicz PM, Nijmeh H, et al. Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. NPJ Precis Oncol. 2021;5(1):91.

Singh AK, Haque M, Madarampalli B, Shi Y, Wildman BJ, Basit A, et al. Corrigendum: Ets-2 Propagates IL-6 Trans-Signaling Mediated Osteoclast-Like Changes in Human Rheumatoid Arthritis Synovial Fibroblast. Front Immunol. 2021;12:808756.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.